Premium
Exercise‐induced increase in beta‐cell function in type 2 diabetics is dependent on fasting glycemia
Author(s) -
Knudsen Sine Haugaard,
Karstoft Kristian,
Winding Kamilla,
Pedersen Bente Klarlund,
Solomon Thomas Phillip James
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.710.1
Subject(s) - medicine , endocrinology , amylin , arginine , insulin , basal (medicine) , type 2 diabetes , morning , bolus (digestion) , glucagon , diabetes mellitus , chemistry , islet , amino acid , biochemistry
To determine the effect of exercise on beta‐cell function nine type 2 diabetics (T2D; age 62±2 y, BMI 30.3±2.0 kg/m 2 ) with high fasting glucose (HiFG; 10.8±0.8 mmol/l, n=4) and low fasting glucose (LoFG; 6.8±0.6 mmol/l, n=5) were studied. Before and the morning following a 1‐hour treadmill walk (65% HRmax), a hyperglycemic (5.4 mM+basal) clamp was performed combined with infusion of glucagon‐like peptide‐1 (GLP‐1) and a bolus injection of arginine. Arterialised blood glucose was measured every 5 min for adjustments of the glucose infusion rates (GIR; mg/kg/min). Insulin secretion rates (ISR; pmol/min) in response to glucose, GLP‐1 and arginine were deconvoluted from C‐peptide concentrations in acute (0–4 min) and steady state (last 30 min) phase. Exercise did not alter fasting glucose in HiFG or LoFG and the GIR required to maintain hyperglycemia did not differ between trials. Acute ISR arginine was higher (P<0.05) in LoFG compared to HiFG and further increased by exercise (P=0.06). After exercise ISR in response to glucose, GLP‐1 and arginine was higher (all P<0.05) in LoFG compared to HiFG. In T2D with LoFG, insulin secretory capacity and the exercise‐induced increase in ISR was higher. This suggests that the beneficial effects of exercise on beta‐cell function may be dependent on fasting glycemia. EFSD/Amylin Paul Langerhans program grant, The Danish Centre for Strategic Research in Type 2 Diabetes (DD2).